Hemorrhagic Disease

Categories: Blood diseases, Immune diseases, Rare diseases

Aliases & Classifications for Hemorrhagic Disease

MalaCards integrated aliases for Hemorrhagic Disease:

Name: Hemorrhagic Disease 12 15
Hemorrhagic Disorders 43 71
Hemorrhagic Diathesis 12
Hemorrhagic Diseases 54
Bleeding Tendency 71


External Ids:

Disease Ontology 12 DOID:2213
ICD9CM 34 287.9
MeSH 43 D006474
ICD10 32 D68.3 D69.9
UMLS 71 C0019087 C1458140

Summaries for Hemorrhagic Disease

MalaCards based summary : Hemorrhagic Disease, also known as hemorrhagic disorders, is related to vitamin k deficiency bleeding and von willebrand disease, type 2, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Hemorrhagic Disease is F11 (Coagulation Factor XI), and among its related pathways/superpathways are Collagen chain trimerization and Response to elevated platelet cytosolic Ca2+. The drugs Dalteparin and Nadroparin have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and lung, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Hemorrhagic Disease

Diseases in the Hemorrhagic Disease family:

Rare Hemorrhagic Disorder Due to an Acquired Coagulation Factor Defect Hemorrhagic Disease Due to Alpha-1-Antitrypsin Pittsburgh Mutation
Rare Hemorrhagic Disorder Due to a Platelet Anomaly Rare Hemorrhagic Disorder Due to a Coagulation Factors Defect
Rare Hemorrhagic Disorder Rare Hemorrhagic Disorder Due to an Acquired Platelet Anomaly
Rare Hemorrhagic Disorder Due to a Constitutional Thrombocytopenia Rare Hemorrhagic Disorder Due to a Qualitative Platelet Defect
Rare Hemorrhagic Disorder Due to a Constitutional Platelet Anomaly Rare Hemorrhagic Disorder Due to a Constitutional Coagulation Factors Defect

Diseases related to Hemorrhagic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 441)
# Related Disease Score Top Affiliating Genes
1 vitamin k deficiency bleeding 32.5 SERPINC1 F9 F8 F7 F3 F2
2 von willebrand disease, type 2 32.1 VWF GP1BA F8
3 von willebrand disease, type 3 32.1 VWF GP1BA F8
4 alpha-2-plasmin inhibitor deficiency 31.9 SERPINF2 SERPINC1 F8 F7 F2
5 von willebrand disease, type 1 31.6 VWF GP6 GP1BA F8 F3 F2
6 factor vii deficiency 31.6 SERPINC1 F9 F8 F7 F3 F2
7 factor x deficiency 31.5 VWF F9 F7 F5 F3 F2
8 factor xi deficiency 31.3 VWF THBD SERPINC1 F9 F8 F7
9 thrombophilia due to activated protein c resistance 31.0 VWF THBD SERPINF2 SERPINE1 SERPINC1 PLAT
10 hemophilia 30.9 F9 F8 F7
11 polycythemia vera 30.8 VWF THBD F5 F2
12 thrombocytopenic purpura, autoimmune 30.7 GP6 GP1BA F8
13 leech infestation 30.6 SERPINC1 F3 F10
14 placental abruption 30.5 THBD SERPINC1 F5 F2
15 alpha-1-antitrypsin deficiency 30.4 SERPINC1 SERPINA1 F2
16 factor xii deficiency 30.3 VWF SERPINC1 F9 F5 F3 F11
17 compartment syndrome 30.3 SERPINC1 F8 F7 F3 F2
18 qualitative platelet defect 30.3 VWF GP1BA F7 F3 F2
19 bilirubin metabolic disorder 30.2 F9 F3 F2
20 placental insufficiency 30.2 VWF SERPINE1 SERPINC1 F3 F2
21 acute promyelocytic leukemia 30.1 THBD SERPINF2 SERPINE1 SERPINC1 PLAT F3
22 hemophilia b 30.0 VWF SERPINC1 F9 F8 F7 F3
23 bombay phenotype 30.0 VWF FUT2
24 hypothyroidism 29.9 VWF SERPINE1 F9 F8 F3 F2
25 acquired von willebrand syndrome 29.9 VWF GP1BA F9 F8 F7 F3
26 hemopericardium 29.9 F3 F2
27 thrombasthenia 29.9 GP1BA F5 F3 F2
28 purpura 29.8 VWF THBD SERPINC1 GP1BA F3 F2
29 eclampsia 29.8 THBD SERPINE1 SERPINC1 F2
30 acquired hemophilia a 29.8 F9 F8 F5 F3 F11
31 hemophilia a 29.8 VWF F9 F8 F7 F3
32 active peptic ulcer disease 29.7 VWF P2RY12 F7 F3 F2
33 acquired hemophilia 29.7 F9 F8 F5 F3 F11 F10
34 von willebrand's disease 29.7 VWF PLAT P2RY12 GP6 GP1BA F9
35 arteriosclerosis 29.6 THBD SERPINE1 SERPINC1 F3
36 liver cirrhosis 29.6 SERPINF2 SERPINC1 SERPINA1 F3 F2
37 thrombocytosis 29.6 VWF SERPINC1 PPBP F3 F2
38 factor v deficiency 29.5 VWF F9 F8 F7 F5 F3
39 afibrinogenemia, congenital 29.5 VWF SERPINF2 SERPINE1 SERPINC1 PLAT F8
40 thrombotic thrombocytopenic purpura 29.4 VWF THBD SERPINF2 SERPINC1 PLAT F3
41 varicose veins 29.4 VWF THBD SERPINC1 PLAT F5 F2
42 thrombophilia due to thrombin defect 29.4 THBD SERPINE1 SERPINC1 PLAT F8 F5
43 hemarthrosis 29.3 VWF F9 F8 F7 F3 F2
44 prothrombin deficiency 29.3 SERPINC1 F9 F8 F7 F3 F2
45 blood platelet disease 29.3 VWF THBD SERPINC1 GP6 GP1BA F8
46 factor xiii deficiency 29.3 VWF SERPINF2 SERPINE1 SERPINC1 F9 F8
47 heart disease 29.3 VWF SERPINE1 SERPINC1 PPBP PLAT F8
48 factor viii deficiency 29.1 VWF F9 F8 F7 F5 F3
49 essential thrombocythemia 29.0 VWF THBD SERPINE1 SERPINC1 PPBP GP1BA
50 vascular disease 28.8 VWF THBD SERPINE1 SERPINC1 PPBP PLAT

Comorbidity relations with Hemorrhagic Disease via Phenotypic Disease Network (PDN):

Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease

Graphical network of the top 20 diseases related to Hemorrhagic Disease:

Diseases related to Hemorrhagic Disease

Symptoms & Phenotypes for Hemorrhagic Disease

UMLS symptoms related to Hemorrhagic Disease:

angina pectoris, edema, chest pain, abnormal bruising

MGI Mouse Phenotypes related to Hemorrhagic Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.1 F10 F11 F2 F3 F5 F7
2 homeostasis/metabolism MP:0005376 10.09 F10 F11 F2 F3 F5 F7
3 hematopoietic system MP:0005397 10.07 F11 F2 F3 F8 F9 GP1BA
4 immune system MP:0005387 9.73 F11 F2 F3 F8 F9 FUT2
5 mortality/aging MP:0010768 9.5 F10 F11 F2 F3 F5 F7

Drugs & Therapeutics for Hemorrhagic Disease

Drugs for Hemorrhagic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 237)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Dalteparin Approved Phase 4 9005-49-6
Nadroparin Approved, Investigational Phase 4
Abciximab Approved Phase 4 143653-53-6
Tirofiban Approved Phase 4 144494-65-5 60947
Remifentanil Approved Phase 4 132875-61-7 60815
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
Tenecteplase Approved Phase 4 191588-94-0
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
14 Indobufen Investigational Phase 4 63610-08-2
Chitosan Experimental Phase 4 9012-76-4 71853
16 Plasminogen Phase 4
17 Charcoal Phase 4
18 Antidotes Phase 4
19 Tissue Plasminogen Activator Phase 4
20 Heparin, Low-Molecular-Weight Phase 4
21 Hemostatics Phase 4
22 Narcotics Phase 4
23 Analgesics, Opioid Phase 4
24 Chelating Agents Phase 4
25 Dialysis Solutions Phase 4
26 Analgesics Phase 4
27 Calcium, Dietary Phase 4
28 Central Nervous System Depressants Phase 4
29 Hormones Phase 4
30 Tranquilizing Agents Phase 4
31 Psychotropic Drugs Phase 4
32 Anti-Anxiety Agents Phase 4
33 Anticonvulsants Phase 4
34 Betamethasone-17,21-dipropionate Phase 4
35 Betamethasone Valerate Phase 4 2152-44-5
36 Betamethasone benzoate Phase 4
37 calcium channel blockers Phase 4
38 Betamethasone sodium phosphate Phase 4
39 Fibrinolytic Agents Phase 4
40 Platelet Aggregation Inhibitors Phase 4
41 calcium heparin Phase 4
42 Neurotransmitter Agents Phase 4
43 Purinergic P2Y Receptor Antagonists Phase 4
Diclofenac Approved, Vet_approved Phase 2, Phase 3 15307-86-5 3033
Ketorolac Approved Phase 3 66635-83-4, 74103-06-3 3826
Etoricoxib Approved, Investigational Phase 3 202409-33-4 123619
Bortezomib Approved, Investigational Phase 3 179324-69-7 93860 387447
Turmeric Approved, Experimental, Investigational Phase 3
Vorinostat Approved, Investigational Phase 3 149647-78-9 5311
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244

Interventional clinical trials:

(show top 50) (show all 132)
# Name Status NCT ID Phase Drugs
1 Prospective Non-randomized Trial Comparing Holmium Laser Enucleation of the Prostate Versus Greenlight Laser Photoselective Vaporization of the Prostate in Treating Benign Prostate Hyperplasia in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
2 the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy Unknown status NCT03230851 Phase 4 aspirin 100mg/d therapy;aspirin 100mg/2d therapy;aspirin 100mg/3d therapy;aspirin 50mg bid therapy;aspirin 75mg/d therapy;aspirin 50mg/d therapy;indobufen 100mg bid therapy
3 Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants Unknown status NCT02969746 Phase 4 Activated Charcoal
4 Low Dose Rt-PA Plus LMWH Compared With LMWH Alone for the Treatment of Normotensive Pulmonary Embolism Patients With Acute RV Dysfunction: A Randomized,Multi-Center,Controlled Trial Unknown status NCT01531829 Phase 4 Recombinant tissue plasminogen activator (rt-PA);Low Molecular Weight Heparin
5 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
6 Conventional Versus Point-of-care Based Coagulation Management in Cardiac Surgery Patients Suffering From Increased Bleeding Tendency - a Prospective and Randomized Study Completed NCT00997841 Phase 4
7 FATA: Comparison Between Tirofiban and Abciximab in Facilitated Angioplasty With Stent Implantation: Randomized Multicentre Study Completed NCT00383136 Phase 4 tirofiban high-bolus dose regimen;Abciximab
8 Can Opioid-induced Hyperalgesia be Prevented by Gradual Dose Reduction vs. Abrupt Withdrawal of Remifentanil? Completed NCT01702389 Phase 4 Remifentanil
9 Citrate-based Regional Anticoagulation Versus Heparin for Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Renal Failure: a Randomized Controlled Trial Completed NCT01269112 Phase 4
10 USF Hemostasis: USage of HemCon for Femoral Hemostasis After Percutaneous Completed NCT00716365 Phase 4
11 Post-marketing Investigation (PMI) to Assess Safety and Efficacy of Jivi (BAY 94-9027) Treatment in Participants With Hemophilia A Recruiting NCT04085458 Phase 4 Damoctocog alfa pegol (Jivi, BAY94-9027)
12 Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled Trial Recruiting NCT03771378 Phase 4 rhTPO;eltrombopag
13 CT-guided Ganglion Impar Block for Management of Phantom Rectal Pain Syndrome Recruiting NCT03694639 Phase 4
14 TRIANA: A Randomized Trial to Compare the Efficay and Safety of Thrombolysis With Primary Angioplasty as Initial Reperfusion Therapy in Older Patients (>= 75 Years Old) With Acute Myocardial Infarction Terminated NCT00257309 Phase 4 Tenecteplase + UFH (+ clopidogrel, since 01/97)
15 Does An Abnormal PFA 100 Predict Bleeding After Renal Biopsy? Terminated NCT00334204 Phase 4
16 The Influence of High-Dose Aprotinin and Tranexamic Acid on Bleeding Tendency and Allogeneic Blood Transfusion in Patients Undergoing Primary Aortic Valve Replacement or Coronary Artery Revascularization Unknown status NCT00396760 Phase 3 aprotinin or tranexamic acid
17 Comparative Study Between the Effect of Diclofanic and Ketorolac in Post Tonsillectomy Pain Management Unknown status NCT03178539 Phase 2, Phase 3 diclofenac;ketorolac
18 Association of FC Gamma RIIIA Polymorphism and Thrombopoietin (THPO) Expression With Response to TPO Agonists in Refractory ITP and the Impact of Therapy on B and T Cells Subsets in the Patients With Mutated Genotypes Unknown status NCT02877212 Phase 3 Eltrombopag
19 Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies Completed NCT01178294 Phase 2, Phase 3
20 Prospective Study Comparing EUS Guided Biliary Drainage and ERCP With Stent Placement for Malignant Biliary Obstruction Completed NCT01421836 Phase 2, Phase 3
21 Etoricoxib for Routine Post-operative Pain Prophylaxis in Laparoscopic Gynaecologic Surgery With Expected Need of Post-operative Opioids Completed NCT00373464 Phase 3 etoricoxib
22 A Randomized, Double Blind, Placebo-controlled Crossover Study on the Effect of Commonly Used Herbal Products on Platelet Function and Coagulation Profile of Healthy Volunteers Completed NCT02008981 Phase 3 Curcuma longa;Angelica sinensis;Siwu Tang;Aspirin
23 Cooperative Study of Factor VIII Inhibitors Completed NCT00000582 Phase 3 factor ix
24 An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK0683) or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma Completed NCT00773747 Phase 3 vorinostat;bortezomib;placebo to vorinostat
25 Effect of Ascorbic Acid Administration on Intraoperative Blood Loss and Wound Healing in Total Abdominal Hysterectomy Recruiting NCT03965637 Phase 3 vitamin C
26 ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX Recruiting NCT03417245 Phase 3 fitusiran;factor VIII or factor IX
27 ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX Recruiting NCT03417102 Phase 3 fitusiran;recombinant Factor VIIa and FEIBA
28 Enteric-coated Aspirin for Prevention of Postsurgical Recurrence and Metastasis in Asian Colorectal Cancer Patients (the APREMEC Trial): a Large-scale Multicenter Randomized Double-blind Placebo-controlled Trial Recruiting NCT02607072 Phase 3 Acetylsalicylic acid (ASA)/aspirin 200 mg daily;Acetylsalicylic acid (ASA)/aspirin 100 mg daily;Placebo
29 Safety and Efficacy of Magnesium Sulphate as an Adjuvant to Levobupivacaine in Ultra-sound Guided Transversus Abdominis Plan Block in Pediatric Abdominal Cancer Surgery Recruiting NCT03979599 Phase 3 magnesium sulphate& levobupivacaine;Levobupivacaine
30 Sclerotherapy With Polidocanol Foam In The Management Of First, Second And Third-Grade Hemorrhoidal Disease In Patients With Bleeding Disorders: A Prospective Cohort Study Recruiting NCT04188171 Phase 2, Phase 3
31 Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Efficacy and Safety of Topical Application of Tranexamic Acid for Saving Blood Losses in Patients Subjected to Prosthetic Knee Surgery Active, not recruiting NCT03386656 Phase 3 Amchafibrin
32 Pharmacokinetic Study of Lipo-PGE1 for Prevention of VOD After HSCT Active, not recruiting NCT02338440 Phase 2, Phase 3 lipoprostaglandin E1
33 Phase 3 Study To Evaluate Efficacy/Safety of Valoctocogene Roxaparvovec an AAV Vector-Mediated Gene Transfer of hFVIII at a Dose of 4E13vg/kg in Hemophilia A Patients With Residual FVIII Levels ≤1IU/dL Receiving Prophylactic FVIII Infusions Active, not recruiting NCT03392974 Phase 3
34 A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients With Residual FVIII Levels ≤ 1 IU/dL Receiving Prophylactic FVIII Infusions Active, not recruiting NCT03370913 Phase 3
35 Does Cleansing of Suction Blood During Cardiac Surgery With Heart and Lung Machine Reduce the Postoperative Inflammatory Response ? Terminated NCT00159926 Phase 3
36 Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Patients With Congenital Hemophilia A With Factor VIII Inhibitors Terminated NCT01434511 Phase 3
37 A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Terminated NCT01773187 Phase 3 Pacritinib;Best Available Therapy
38 A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Terminated NCT02055781 Phase 3 Pacritinib;Best Available Therapy
39 Pharmacokinetics, Safety and Efficacy of Recombinant Factor IX Product, IB1001, in Patients With Severe Hemophilia B Withdrawn NCT02048111 Phase 3
40 Prophylactic Oxytocin Before Versus After Placental Delivery to Reduce Blood Loss in Vaginal Delivery Unknown status NCT03006380 Phase 2 oxytocin
41 A Multi-center Randomized Clinical Trial of Regulating Gut Microbiota by Probiotic Agents in Management of Immune Thrombocytopenia Unknown status NCT03033199 Phase 2 Probiotic Agent;Dexamethasone
42 Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury and Post Operative Bleeding in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass: Double-blind, Placebo-controlled Pilot Study Unknown status NCT02191839 Phase 1, Phase 2 Alpha 1-Antitrypsin
43 Eltrombopag for Inherited Thrombocytopenias Completed NCT02422394 Phase 2 Eltrombopag
44 Effect of Sildenafil on Digital Ulcers in Systemic Sclerosis Completed NCT00624273 Phase 2 Sildenafil therapy
45 An Exploratory Phase II Dose Escalation Study of Eltrombopag in MYH9 Related Disease Completed NCT01133860 Phase 2 eltrombopag
46 A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma Completed NCT01183949 Phase 1, Phase 2 AT7519M;Bortezomib
47 Effect of Omega-3 Fatty Acids on Methotrexate Induced Hepatotoxicity in Children With Acute Lymphoblastic Leukemia Completed NCT02373579 Phase 2 Omega-3 Fatty Acids;Methotrexate
48 A Phase Ib/II, Open-label, Multi-center, Dose-finding Study to Assess the Safety and Efficacy of the Oral Combination of LDE225 and INC424 (Ruxolitinib) in Patients With Myelofibrosis Completed NCT01787552 Phase 1, Phase 2 LDE225;INC424
49 Efficacy of Thalidomide in the Treatment of Severe Recurrent Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Completed NCT01485224 Phase 2 Thalidomide
50 A Randomized Double Blind Placebo Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin (IVIG) in Children With Japanese Encephalitis in Nepal Completed NCT01856205 Phase 2 Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]

Search NIH Clinical Center for Hemorrhagic Disease

Cochrane evidence based reviews: hemorrhagic disorders

Genetic Tests for Hemorrhagic Disease

Anatomical Context for Hemorrhagic Disease

MalaCards organs/tissues related to Hemorrhagic Disease:

Liver, Testes, Lung, T Cells, Endothelial, Heart, Prostate

Publications for Hemorrhagic Disease

Articles related to Hemorrhagic Disease:

(show top 50) (show all 1751)
# Title Authors PMID Year
Gross hematuria due to acquired haemophilia in hereditary hemorrhagic telangiectasia. 61 54
18832920 2008
Genetic diagnosis of haemophilia and other inherited bleeding disorders. 61 54
16684001 2006
[Type 2B and pseudo type 2B Von Willebrand disease; a report of three cases]. 61 54
16176858 2006
High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. 61 54
16091456 2005
Carrier detection and prenatal diagnosis of hemophilia in developing countries. 61 54
16276463 2005
[Coagulation disorders following severe trauma: surgeon's role in prevention]. 54 61
15605516 2004
Severe congenital factor X deficiency with intracranial bleeding in two siblings. 61 54
15036435 2004
Factor VIII inhibitor with catalytic activity towards factor VIII. 54 61
11187883 2000
[Study on genetic mutations of the vWF in type 2A von Willebrand disease]. 61 54
10932002 2000
Catalytic activity of antibodies against factor VIII in patients with hemophilia A. 61 54
10470082 1999
Hemorrhagic and thrombotic disorders due to factor V deficiencies and abnormalities: an updated classification. 61 54
9597197 1998
Elephant Endotheliotropic Herpesvirus Hemorrhagic Disease in Asian Elephant Calves in Logging Camps, Myanmar. 61
31855135 2020
Cryo-EM Structure of the African Swine Fever Virus. 61
31787524 2019
Glycyrrhizic acid modulates the atrazine-induced apoptosis in rabbit spleen. 61
31659708 2019
Fatal lancehead pit viper (Bothrops spp.) envenomation in horses. 61
31499078 2019
Identification and complete-genome phylogenetic analysis of an epizootic hemorrhagic disease virus serotype 7 strain isolated in China. 61
31538253 2019
A real-time reverse-transcription isothermal recombinase polymerase amplification assay for the rapid detection of genotype III grass carp (Ctenopharyngodon idella) reovirus. 61
31843672 2019
Current use and development of fish vaccines in China. 61
31821845 2019
Recombinant subunit vaccines protect guinea pigs from lethal Ebola virus challenge. 61
31324500 2019
Lethal hemorrhagic disease and clinical illness associated with the elephant EEHV1 virus are caused by primary infection: Implications for the detection of diagnostic proteins. 61
31723022 2019
Subclinical infection of captive Asian elephants (Elephas maximus) in Thailand with elephant endotheliotropic herpesvirus. 61
31784909 2019
Comparison of the blood parameters and histopathology between grass carp infected with a virulent and avirulent isolates of genotype II grass carp reovirus. 61
31707078 2019
[Diagnostic performance of κ/λ serum free light chain ratio (Freelite® assay) and IgGκ/IgGλ ratio (Hevylite® assay) as prognostic biomarkers of the evolution of immune thrombocytopenia into a chronic disease in adult patients]. 61
31722837 2019
Recombinant Lactobacillus casei Expressing Capsid Protein VP60 can Serve as Vaccine Against Rabbit Hemorrhagic Disease Virus in Rabbits. 61
31684059 2019
Bioinformatics analysis of capsid protein of different subtypes rabbit hemorrhagic disease virus. 61
31775738 2019
Detection of a novel reassortant epizootic hemorrhagic disease virus serotype 6 in cattle in Trinidad, West Indies, containing nine RNA segments derived from exotic EHDV strains with an Australian origin. 61
31238112 2019
Monitoring of the novel rabbit haemorrhagic disease virus type 2 (GI.2) epidemic in European wild rabbits (Oryctolagus cuniculus) in southern Spain, 2013-2017. 61
31521392 2019
Hsp90 Chaperones Bluetongue Virus Proteins and Prevents Proteasomal Degradation. 61
31375577 2019
Bile Salts Alter the Mouse Norovirus Capsid Conformation: Possible Implications for Cell Attachment and Immune Evasion. 61
31341042 2019
Neutrophil-to-lymphocyte ratio, nucleated red blood cells and erythrocyte abnormalities in canine systemic inflammatory response syndrome. 61
31493682 2019
Epidemiology of Bluetongue Virus and Epizootic Hemorrhagic Disease Virus in Beef Cattle on a Ranch in South-Central Florida. 61
31135300 2019
Pediatric Stroke: A Single-Center Experience. 61
31259821 2019
Lethal Infection of Lassa Virus Isolated from a Human Clinical Sample in Outbred Guinea Pigs without Adaptation. 61
31554720 2019
Global Risk and Elimination of Yellow Fever Epidemics. 61
31545372 2019
Ebola Virus: Pathogenesis and Countermeasure Development. 61
31567063 2019
Severe serous cavity bleeding caused by acquired factor V deficiency associated with lymphatic leakage in a hemodialysis patient: A case report. 61
31559292 2019
Inactivated Rabies Virus-Based Ebola Vaccine Preserved by Vaporization Is Heat-Stable and Immunogenic Against Ebola and Protects Against Rabies Challenge. 61
31374568 2019
Genetic characterization and phylogenetic analysis of rabbit hemorrhagic disease virus isolated in Tunisia from 2015 to 2018. 61
31177352 2019
Presence of bluetongue and epizootic hemorrhagic disease viruses in Egypt in 2016 and 2017. 61
31051272 2019
Laboratory evaluation of stable isotope labeling of Culicoides (Diptera: Ceratopogonidae) for adult dispersal studies. 61
31439006 2019
Adenovirus-vectored African Swine Fever Virus antigen cocktails are immunogenic but not protective against intranasal challenge with Georgia 2007/1 isolate. 61
31282366 2019
Immune cell pathology in rabbit hemorrhagic disease. 61
31641316 2019
31403899 2019
An evaluation of the different biomarkers to discriminate bleeding in Crimean-Congo Hemorrhagic Fever. 61
31151923 2019
[Research Progress on Immune Mechanism of Immune Thrombocytopenia--Review]. 61
31418400 2019
Bleeding with negative coagulation screening test as initial presentation of chronic myelogenous leukemia managed by fresh frozen plasma: A case report. 61
31464946 2019
Lesson learned from the investigation and response of Lassa fever outbreak, Margibi County, Liberia, 2018: case report. 61
31296177 2019
Habitat associations of Culicoides species (Diptera: Ceratopogonidae) abundant on a commercial cervid farm in Florida, USA. 61
31349854 2019
Characterization of protective humoral and cellular immune responses against RHDV2 induced by a new vaccine based on recombinant baculovirus. 61
31182325 2019
Acquired Hemophilia A with Gastrointestinal Bleeding. 61
31280527 2019

Variations for Hemorrhagic Disease

Expression for Hemorrhagic Disease

Search GEO for disease gene expression data for Hemorrhagic Disease.

Pathways for Hemorrhagic Disease

Pathways related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
Show member pathways
12.68 THBD SERPINC1 F9 F8 F7 F5
Show member pathways
Show member pathways
Show member pathways
6 11.86 VWF P2RY12 GP6 GP1BA F2
Show member pathways
11.81 F9 F7 F2 F10
8 11.71 THBD SERPINE1 F3
Show member pathways
11.69 VWF GP1BA F2
10 11.41 VWF P2RY12 GP6 F2
11 10.8 F9 F7 F2 F10
12 10.75 VWF GP6 GP1BA
14 10.51 VWF GP1BA

GO Terms for Hemorrhagic Disease

Cellular components related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.32 THBD SERPINE1 SERPINC1 P2RY12 GP6 GP1BA
2 extracellular exosome GO:0070062 10.15 VWF SERPINF2 SERPINE1 SERPINC1 SERPINA1 PLAT
3 extracellular region GO:0005576 10.13 VWF SERPINF2 SERPINE1 SERPINC1 SERPINA1 PPBP
4 cell surface GO:0009986 9.95 THBD SERPINF2 PLAT P2RY12 GP6 GP1BA
5 endoplasmic reticulum lumen GO:0005788 9.92 SERPINC1 SERPINA1 F9 F8 F7 F5
6 Golgi lumen GO:0005796 9.73 F9 F7 F2 F10
7 endoplasmic reticulum-Golgi intermediate compartment membrane GO:0033116 9.7 SERPINA1 F8 F5
8 platelet alpha granule lumen GO:0031093 9.7 VWF SERPINF2 SERPINE1 SERPINA1 PPBP F8
9 COPII-coated ER to Golgi transport vesicle GO:0030134 9.69 SERPINA1 F8 F5
10 collagen-containing extracellular matrix GO:0062023 9.65 VWF SERPINF2 SERPINE1 SERPINC1 SERPINA1 PLAT
11 platelet alpha granule GO:0031091 9.54 VWF F5
12 extracellular space GO:0005615 9.53 THBD SERPINF2 SERPINE1 SERPINC1 SERPINA1 PPBP
13 intrinsic component of external side of plasma membrane GO:0031233 9.49 F3 F10
14 serine-type peptidase complex GO:1905286 9.46 F7 F3

Biological processes related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 10.03 PLAT F9 F7 F2 F11 F10
2 ER to Golgi vesicle-mediated transport GO:0006888 9.95 SERPINA1 F9 F8 F7 F5 F2
3 platelet activation GO:0030168 9.91 VWF P2RY12 GP6 GP1BA F8 F2
4 cellular protein metabolic process GO:0044267 9.9 SERPINC1 SERPINA1 F5 F2
5 positive regulation of protein kinase B signaling GO:0051897 9.87 P2RY12 F7 F3 F10
6 negative regulation of endopeptidase activity GO:0010951 9.85 SERPINF2 SERPINE1 SERPINC1 SERPINA1
7 negative regulation of peptidase activity GO:0010466 9.83 SERPINF2 SERPINE1 SERPINC1 SERPINA1
8 hemostasis GO:0007599 9.83 VWF THBD SERPINC1 SERPINA1 P2RY12 GP6
9 acute-phase response GO:0006953 9.8 SERPINF2 SERPINA1 F8 F2
10 platelet degranulation GO:0002576 9.8 VWF SERPINF2 SERPINE1 SERPINA1 PPBP F8
11 COPII vesicle coating GO:0048208 9.76 SERPINA1 F8 F5
12 regulation of blood coagulation GO:0030193 9.76 SERPINC1 GP1BA F2 F11
13 fibrinolysis GO:0042730 9.72 SERPINF2 SERPINE1 PLAT GP1BA F2
14 positive regulation of blood coagulation GO:0030194 9.69 SERPINE1 F7 F2
15 negative regulation of fibrinolysis GO:0051918 9.67 THBD SERPINF2 SERPINE1 F2
16 blood coagulation, extrinsic pathway GO:0007598 9.65 F7 F3 F10
17 blood coagulation, intrinsic pathway GO:0007597 9.63 VWF GP1BA F9 F8 F2 F11
18 negative regulation of blood coagulation GO:0030195 9.62 THBD SERPINE1
19 positive regulation of positive chemotaxis GO:0050927 9.61 F7 F3
20 plasminogen activation GO:0031639 9.61 PLAT F11
21 negative regulation of platelet activation GO:0010544 9.59 THBD F2
22 negative regulation of plasminogen activation GO:0010757 9.58 SERPINF2 SERPINE1
23 positive regulation of platelet-derived growth factor receptor signaling pathway GO:0010641 9.54 F7 F3
24 blood coagulation GO:0007596 9.53 VWF THBD SERPINC1 SERPINA1 PLAT P2RY12

Molecular functions related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.36 VWF THBD SERPINF2 SERPINE1 SERPINC1 SERPINA1
2 peptidase activity GO:0008233 9.85 PLAT F9 F7 F2 F11 F10
3 serine-type peptidase activity GO:0008236 9.63 PLAT F9 F7 F2 F11 F10
4 peptidase inhibitor activity GO:0030414 9.62 SERPINF2 SERPINE1 SERPINC1 SERPINA1
5 serine-type endopeptidase inhibitor activity GO:0004867 9.56 SERPINF2 SERPINE1 SERPINC1 SERPINA1
6 protease binding GO:0002020 9.43 VWF SERPINF2 SERPINE1 SERPINC1 SERPINA1 F3
7 serine-type endopeptidase activity GO:0004252 9.17 PLAT F9 F7 F3 F2 F11

Sources for Hemorrhagic Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....